6.52

4.32% 0.27

After Hours: 6.53 0.01 +0.15%

Diamedica Therapeutics Inc (DMAC)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Diamedica Therapeutics Inc stock is traded at $6.52, with a volume of 184.77K. It is up +4.32% in the last 24 hours and down -1.51% over the past month. DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Previous Close:

$6.25

Open:

$6.34

24h Volume:

184.77K

Relative Volume:

0.96

Market Cap:

$351.31M

Revenue:

Net Income/Loss:

$-32.77M

P/E Ratio:

-9.337

EPS:

-0.6983

Net Cash Flow:

$-29.56M

1W Performance:

+9.40%

1M Performance:

-1.51%

6M Performance:

+4.82%

1Y Performance:

+68.91%

1-Day Range:

$6.06

$6.57

1-Week Range:

$5.81

$6.57

52-Week Range:

$3.475

$10.42

Diamedica Therapeutics Inc Stock (DMAC) Company Profile

Name

Diamedica Therapeutics Inc

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

(763) 496-5454

Address

301 CARLSON PARKWAY, MINNEAPOLIS, MN

Employee

Twitter

@diamedica

Next Earnings Date

2026-05-06

Latest SEC Filings

DMAC's Discussions on Twitter

Compare DMAC vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DMAC Diamedica Therapeutics Inc	6.52	336.77M	0	-32.77M	-29.56M	-0.6983
VRTX Vertex Pharmaceuticals Inc	427.65	107.87B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	721.05	73.63B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	807.55	49.42B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	303.00	40.20B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	313.32	33.06B	5.36B	287.73M	924.18M	2.5229

Diamedica Therapeutics Inc Stock (DMAC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-14-25	Resumed	Cantor Fitzgerald	Overweight
Oct-30-25	Initiated	TD Cowen	Buy
Oct-07-24	Initiated	H.C. Wainwright	Buy
Apr-24-24	Resumed	Craig Hallum	Buy
Jun-22-23	Upgrade	Oppenheimer	Perform → Outperform
Apr-09-21	Initiated	Oppenheimer	Outperform
Feb-17-21	Initiated	ROTH Capital	Buy
Oct-30-20	Initiated	Guggenheim	Buy
Jul-08-20	Initiated	Maxim Group	Buy
Apr-30-19	Initiated	Dougherty & Company	Buy
Mar-05-19	Initiated	Lake Street	Buy

View All

Diamedica Therapeutics Inc Stock (DMAC) Latest News

May 05, 2026

MSN Money - MSN

May 05, 2026

May 04, 2026

DiaMedica Therapeutics Inc expected to post a loss of 18 cents a shareEarnings Preview - TradingView

May 04, 2026

May 03, 2026

DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The National Law Review

May 03, 2026

May 02, 2026

DiaMedica Therapeutics (DMAC) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat

May 02, 2026

Apr 30, 2026

DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026 - BioSpace

Apr 30, 2026

Apr 27, 2026

Top Wall Street forecasters revamp DiaMedica Therapeutics expectations ahead of Q4 earnings - MSN

Apr 27, 2026

Apr 24, 2026

DMAC Price Today: DiaMedica Therapeutics Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange

Apr 24, 2026

Apr 23, 2026

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

Apr 23, 2026

DMAC DiaMedica Therapeutics Inc. reports narrower Q4 2025 loss than consensus forecasts, its stock rises modestly in today’s trading.Expert Market Insights - Cổng thông tin điện tử tỉnh Tây Ninh

Apr 23, 2026

Apr 22, 2026

Is DiaMedica (DMAC) stock worth committing funds to (Drifts Higher) 2026-04-22Community Risk Signals - Cổng thông tin điện tử tỉnh Lào Cai

Apr 22, 2026

Apr 16, 2026

DiaMedica Therapeutics Highlights DM199 Preeclampsia Data, Stroke Interim Catalyst at RedChip Conference - MarketBeat

Apr 16, 2026

Apr 13, 2026

EBITDA per share of DiaMedica Therapeutics Inc. – NASDAQ:DMAC - TradingView

Apr 13, 2026

Is DiaMedica Therapeutics Inc a cyclical or defensive stock2026 Market Sentiment & Precise Swing Trade Alerts - baoquankhu1.vn

Apr 13, 2026

Apr 10, 2026

Returns Recap: How does DiaMedica Therapeutics Inc compare to its peers2026 Geopolitical Influence & Technical Entry and Exit Tips - baoquankhu1.vn

Apr 10, 2026

Apr 07, 2026

RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms - marketscreener.com

Apr 07, 2026

Apr 06, 2026

Should I Buy DiaMedica (DMAC) Stock Today | Price at $6.62, Up 2.16%Community Watchlist - Newser

Apr 06, 2026

Apr 03, 2026

Q1 EPS Estimate for DiaMedica Therapeutics Raised by Analyst - MarketBeat

Apr 03, 2026

What is HC Wainwright’s Forecast for DMAC FY2029 Earnings? - Defense World

Apr 03, 2026

Apr 02, 2026

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Diamedica Therapeutics (DMAC), Elevance Health (ELV) and Oric Pharmaceuticals (ORIC) - The Globe and Mail

Apr 02, 2026

HC Wainwright Issues Pessimistic Estimate for DMAC Earnings - MarketBeat

Apr 02, 2026

Apr 01, 2026

[ARS] DiaMedica Therapeutics Inc. SEC Filing - Stock Titan

Apr 01, 2026

Equity plan expansion at DiaMedica (NASDAQ: DMAC) adds 3.5M shares - Stock Titan

Apr 01, 2026

H.C. Wainwright reiterates DiaMedica stock rating on trial progress By Investing.com - Investing.com India

Apr 01, 2026

H.C. Wainwright reiterates DiaMedica stock rating on trial progress - Investing.com

Apr 01, 2026

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2025 Earnings Call Transcript - Insider Monkey

Apr 01, 2026

Mar 31, 2026

DiaMedica Therapeutics Furnishes 2025 Financial Results and Business Update - The Globe and Mail

Mar 31, 2026

DMAC Should I Buy - Intellectia AI

Mar 31, 2026